SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation G681A

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 A Phase 1 Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as Part of a Neoadjuvant Regimen in Patients With Locally Advanced Pancreatic Cancer

This phase I trial is studying the side effects and best dose of stereotactic radiation therapy and nelfinavir mesylate when given together with gemcitabine hydrochloride, leucovorin calcium, and fluorouracil in treating patients with locally advanced pancreatic cancer. Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Drugs, such as nelfinavir mesylate, may make tumor cells more sensitive to radiation therapy. Drugs used in chemotherapy, such as gemcitabine hydrochloride, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving stereotactic radiation therapy and nelfinavir mesylate together with combination chemotherapy may kill more tumor cells.

NCT01068327 Adenocarcinoma of the Pancreas Stage III Pancreatic Cancer Drug: gemcitabine hydrochloride Drug: leucovorin calcium Drug: fluorouracil Drug: nelfinavir mesylate Radiation: stereotactic body radiation therapy Radiation: hypofractionated radiation therapy Procedure: therapeutic conventional surgery
MeSH: Adenocarcinoma Pancreatic Neoplasms
HPO: Neoplasm of the pancreas

The pharmacokinetic parameters will be presented as the mean and standard deviation.. Pharmacogenomic status of CYP2C19*2 (G681A) (correlative). --- G681A ---

To measure the pharmacogenomic status of CYP2C19*2 (G681A) in the study population. --- G681A ---

Primary Outcomes

Description: Due to delayed toxicities attributable to radiotherapy, all toxicities observed within 1 month of surgery will be scored. Toxicity will be graded and tabled by dose levels.

Measure: Dose-limiting toxicity as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0

Time: Within 1 month of surgery

Description: The MTD of SRT/nelfinavir mesylate is defined as the highest dose level at which no greater than one dose-limiting toxicity is observed in 6 patients.

Measure: Maximally tolerated dose (MTD) of stereotactic radiotherapy and concurrent nelfinavir mesylate

Time: 3 patients will initially be treated at each dose level (4 levels); a minimum of 1 month of observation after surgery is required in all 3 patients before escalation

Secondary Outcomes

Description: At the MTD, the rate of surgical complete resection with 90% exact binomial confidence intervals will be calculated.

Measure: Rate of complete surgical resection

Time: At the time of surgery (2-3 weeks after completion of SRT)

Description: At the MTD, the rate of pathologic response with 90% exact binomial confidence intervals will be calculated.

Measure: Pathological response

Time: Pre- to post-treatment

Description: Pre- to post-treatment changes in tumor size on CT or MRI scan (if CT is not sufficient).

Measure: Tumor response on CT/MRI

Time: Change from pre- to post-treatment

Measure: Correlation between the radiologic response and pathologic response

Time: Pre- to post-treatment

Description: Exploratory analyses will compare pre- to post-nelfinavir mesylate treatment changes in Akt levels between patients who achieve or do not achieve R0 resection by the nonparametric Wilcoxon rank sum test.

Measure: Phospho-AKT expression in pancreatic tumor tissue (correlative)

Time: Pre- to post-nelfinavir mesylate

Description: The data will be modeled using WinNonLin Pro version 4.1. The pharmacokinetic parameters will be presented as the mean and standard deviation.

Measure: Pharmacokinetics of nelfinavir mesylate (correlative)

Time: After at least 1 week of NFV: *0 h (trough); *After NFV dosing: 1, 2, 3, 4, 5, 6, 8, and 12 h

Description: There is currently insufficient clinical data to indicate whether any of the specific polymorphisms proposed to be studied, particularly those subjects with a heterozygous state, will correlate with meaningful differences in the pharmacokinetic parameters of nelfinavir mesylate. These analyses must therefore be exploratory in nature.

Measure: Pharmacogenomic status of CYP2C19*2 (G681A) (correlative)

Time: Enrollment, at the time of planned tumor tissue procurement, and at the time that re-staging studies are done


HPO Nodes


Neoplasm of the pancreas
Genes 105
MGMT BRCA1 MLH1 PMS2 RAD51C TERC CDKN2B PALLD TSC2 CHEK2 SMAD4 NTHL1 RAD51D CTC1 MSH6 NOP10 KRAS NHP2 BAP1 PDGFRB FAN1 KRAS BRD4 RNF43 CDKN2B TP53 MSH2 CDKN2A SPINK1 RTEL1 CDKN2C VHL PIK3CA CDK4 PARN BRCA2 KRAS TERF2IP CHEK2 CDKN1A RPS20 BRCA1 USB1 PRKAR1A POT1 TERT APC CDKN2A CCND1 STK11 TP53 COL14A1 NUTM1 MDM2 TSC1 BRCA2 SLC12A3 EWSR1 CDC73 CDKN1B ACD CDC73 BRIP1 MRE11 GCGR TP53 STK11 EPCAM MEN1 NPM1 WRAP53 TGFBR2 SEMA4A TINF2 MITF BMPR1A TP53 NOTCH3 DKC1 BARD1 AAGAB SMAD4 RAD50 STK11 NBN MLH3 PALB2 PALB2 CDKN2A WT1 BRCA2 MAFA MC1R MEN1 RAD51 CDC73 CLCNKB TP53 CDKN1B FLI1 PTEN PMS1 CDKN2A TERT APC